Should we target signal pathways instead of single mediators in the treatment of sepsis?
Wratten
M L
ML
Clinical and Laboratory Research Department, Bellco SpA, Mirandola/MO, Italy. marylou.wratten@bellcospa.it
Brendolan
A
A
Ronco
C
C
La Greca
G
G
Tetta
C
C
D000209:Acute-Phase Proteins; D002352:Carrier Proteins / Q000502:physiology; D015936:Complement C5a / Q000037:antagonists & inhibitors; D005609:Free Radicals; D006440:Hemofiltration; D006801:Humans; D008081:Liposomes / Q000378:metabolism; D008562:Membrane Glycoproteins; D016328:NF-kappa B / Q000502:physiology; D018805:Sepsis / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D015936:Complement C5a; D005609:Free Radicals; D008081:Liposomes; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D000099231:Lipopolysaccharide-Binding Protein